Search clinical trials for: pneumococcal disease prevention; safety and immunogenicity study

Total 482784 results

GlaxoSmithKline
Affinivax, Inc.

Recruiting

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immunogenicity of AFX3772 Vaccine in Healthy Infants

Pneumococcal Infections | Pneumonia, Pneumococcal | Pneumonia, Bacterial

United States, Puerto Rico
Sinovac Life Sciences Co., Ltd.

Recruiting

Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

Pneumococcal Infections

China
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Not yet recruiting

Immunogenicity and Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in 2-month-old and 3-month-old Healthy Volunteers

Pneumonia, Pneumococcal

China
Pfizer

Active, not recruiting

A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan

Pneumococcal Disease

Taiwan, India
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)

Pneumococcal Disease

United States, Austria, Canada, Denmark, Finland, Israel, Poland, Spain
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)

Pneumococcal Infections

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)

Pneumonia, Pneumococcal

United States, Canada, France, Israel, Italy, Japan, Korea, Republic of, Spain, Taiwan
Matrivax Research and Development Corporation

Active, not recruiting

A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine

Pneumococcal Vaccine

United States
GlaxoSmithKline

Completed

A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers

Diphtheria

Spain, Germany, Italy
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008) (STRIDE-8)

Pneumococcal Infection

United States, Australia, Canada, Chile, Japan, Korea, Republic of, New Zealand, Poland
Pfizer

Completed

Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age

Pneumococcal Disease

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Healthy Volunteers (Meningococcal Infection)

United States, Puerto Rico
Pfizer

Completed

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants

Pneumococcal Disease

Denmark, Belgium, Australia, Poland, Norway, Finland, Netherlands, Italy, Czechia, Estonia, Russian Federation, Slovakia
Walvax Biotechnology Co., Ltd.

Enrolling by invitation

A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13

Pneumococcal Disease, Invasive

Indonesia
Pfizer

Completed

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants

Pneumococcal Disease

United States, Puerto Rico
Pfizer

Completed

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan

Pneumococcal Disease

Korea, Republic of, Taiwan, Japan
GlaxoSmithKline

Active, not recruiting

Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults

Respiratory Syncytial Virus Infections

Spain, United States, Belgium, Poland
CureVac
German Federal Ministry of Education and Research

Completed

A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19

Severe Acute Respiratory Syndrome | Covid19 | SARS-CoV-2 | Coronavirus

Panama, Peru
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Meningococcal Infections

Czechia, Finland, Italy, Poland, Romania, Spain
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)

Pneumonia, Pneumococcal

United States
Pfizer

Completed

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants

Pneumococcal Disease

Japan
Pfizer

Completed

Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2

COVID-19 | Pneumococcal Disease | SARS-CoV-2 Infection

United States
Sinovac Biotech Co., Ltd

Completed

A Study of Booster Immunization With COVID-19 Vaccine,Inactivated Co -Administration With Influenza Vaccine and Pneumococcal Polysaccharide Vaccine

COVID-19

China
Affinivax, Inc.

Completed

A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator

Healthy Volunteers | Pneumococcal Disease

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018) (PNEU-WAY)

Pneumococcal Infections

United States, France, Peru, South Africa, Thailand
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older

Herpes Zoster

United States, Germany, Estonia, Canada
National Institute of Allergy and Infectious Diseases...
Lederle-Praxis Biologicals

Completed

A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants

HIV Infections | Pneumococcal Infections

United States, Puerto Rico
Pfizer

Completed

Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine

Infections, Meningococcal

Australia, Canada, Czechia, Panama, South Africa, Turkey
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)

Pneumococcal Infections

United States, Brazil, Colombia, Dominican Republic, Greece, Italy, Panama
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older

Herpes Zoster | Herpes Zoster Vaccine

United States, Estonia, Canada
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in Toddlers

Infections, Streptococcal

Germany
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)

Pneumococcal Infections

United States, Australia, Canada, Chile, New Zealand, Poland, Russian Federation
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

Measles; Mumps; Rubella | Measles-Mumps-Rubella Vaccine

United States, Finland, Taiwan, Estonia, Puerto Rico
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

Measles | Rubella | Mumps | Measles-Mumps-Rubella Vaccine

Finland, Thailand, United States, Spain, Czechia, Puerto Rico, Malaysia
GlaxoSmithKline

Completed

This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine

Rotavirus Infection | Rotavirus Vaccines

United States
Walvax Biotechnology Co., Ltd.

Completed

Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old)

Diseases Caused by Streptococcus Pneumoniae Serotypes
GlaxoSmithKline

Completed

Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age

Streptococcus Pneumoniae Vaccines | Infections, Streptococcal

Mexico
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria Meni

Poland
GlaxoSmithKline

Completed

Evaluate Safety and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine in Preterm Born Infants.

Streptococcus Pneumoniae Vaccines | Infections, Streptococcal

Spain, Greece
GlaxoSmithKline

Completed

Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age

Streptococcus Pneumoniae | Infections, Streptococcal

India
GlaxoSmithKline

Completed

Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Streptococcus Pneumoniae Vaccines

Spain, Germany, Poland
GlaxoSmithKline

Completed

Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A in Healthy Japanese Children

Infections, Streptococcal

Japan
GlaxoSmithKline

Completed

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

United States
GlaxoSmithKline

Completed

Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age

Measles | Rubella | Mumps

United States, Finland, Estonia, Spain, Mexico, Puerto Rico
GlaxoSmithKline

Completed

Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants

Infections, Streptococcal

Poland, Germany, Czechia, Spain
GlaxoSmithKline

Completed

COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine

Infections, Streptococcal

Argentina, Panama, Colombia
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (Synflorix™) When Administered to Children Who Are at an Increased Risk of Pneumococcal Infection

Streptococcus Pneumoniae Vaccines | Infections, Streptococcal

Russian Federation, Poland
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

Finland, Australia, Spain, Italy, Canada, Czechia
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.

Infections, Streptococcal

Finland, France, Poland
GlaxoSmithKline

Completed

Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment

Infections, Streptococcal

Romania

3

Subscribe